Metoprolol is the Best Choice for This Patient
For a 62-year-old man with a history of myocardial infarction 10 years ago and persistent hypertension (150/100 mmHg), metoprolol (Option E) is the optimal antihypertensive agent. This recommendation is based on the compelling indication of prior MI, which takes precedence over simple hypertension management.
Rationale: Beta Blockers Are First-Line After MI
Beta blockers provide dual benefits in this clinical scenario:
Secondary prevention after MI: Beta blockers reduce all-cause mortality by 23% in long-term trials after MI 1, 2. This mortality benefit is established and robust, particularly in patients with prior MI 3, 4.
Effective blood pressure control: Beta blockers are proven antihypertensive agents that simultaneously address both the hypertension and provide cardioprotection 1.
Guideline-directed therapy: The 2017 ACC/AHA guidelines explicitly recommend beta blockers as first-line therapy for hypertension when it occurs in patients with stable ischemic heart disease (SIHD), which includes patients with prior MI 1.
Why Metoprolol Specifically?
Among beta blockers, metoprolol succinate (sustained-release), carvedilol, bisoprolol, nadolol, propranolol, and timolol are all acceptable GDMT (guideline-directed management and therapy) options 1. Metoprolol is widely studied, well-tolerated, and specifically mentioned in multiple guidelines 3, 4, 5.
Important caveat: Avoid atenolol—it is less effective than other antihypertensive drugs and should not be used 1.
Why Not the Other Options?
Amlodipine (Option A)
- Calcium channel blockers can be used as add-on therapy if beta blockers alone don't control BP 1
- They are second-line, not first-line, in patients with prior MI
- No mortality benefit demonstrated in post-MI patients 3
Clonidine (Option B)
- Not a first-line agent for hypertension in any guideline
- No specific benefit for coronary artery disease
- Reserved for resistant hypertension as add-on therapy
Hydrochlorothiazide (Option C)
- Thiazide diuretics are effective antihypertensives but lack the specific cardioprotective benefits of beta blockers post-MI
- Should be considered as add-on therapy if BP remains uncontrolled on beta blocker 3
- Not first-line when there's a compelling indication for beta blockers
Spironolactone (Option D)
- Aldosterone antagonists are indicated post-MI only if there is LV dysfunction (EF ≤40%), heart failure, or diabetes 3, 4
- This patient has "good general health" with no mention of these conditions
- Would be inappropriate as monotherapy for simple hypertension in this context
Treatment Algorithm for This Patient
Start metoprolol (or another GDMT beta blocker without intrinsic sympathomimetic activity)
- Target dose: 50-200 mg twice daily for metoprolol tartrate, or sustained-release formulation once daily 5
Add ACE inhibitor or ARB if:
Add dihydropyridine CCB or thiazide diuretic if:
Target Blood Pressure
- Goal: <130/80 mmHg 3, 7
- Exercise caution if diastolic BP falls below 60 mmHg, as this may worsen myocardial ischemia in patients with coronary disease 3
Duration of Therapy
While the AHA/ACCF guidelines suggest a minimum 3-year treatment course with beta blockers for uncomplicated MI 1, 2, most patients continue indefinitely because they often have concurrent hypertension (as in this case) or develop other indications over time 2.
Common Pitfall to Avoid
Do not withhold beta blockers in stable patients with remote MI simply because "it's been 10 years." The mortality benefit persists, and the hypertension provides an additional compelling reason for continued therapy 1, 6.